Investigational drug · Phase 3
sepofarsen
Also called: QR-110
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "sepofarsen"
First trial start
2019
Apr 4, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "sepofarsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leber Congenital Amaurosis 10
- Blindness
- Leber Congenital Amaurosis
- Sensation Disorders
- Eye Diseases, Hereditary
- Eye Diseases
- Eye Disorders Congenital
- Retinal Disease
- Vision Disorder
- Neurological Manifestations
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "sepofarsen" as an intervention, largest first.
- A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)Pivotal-lookingActive, not recruiting
ProQR TherapeuticsIndustry
NCT03913143 · 36 participants · Start Apr 4, 2019 · Primary completion Jan 31, 2022
Drug: sepofarsen · For: Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis and 7 more
Sites: Iowa City, Iowa; Ghent, Belgium; Belo Horizonte, Brazil · 14 sites in all
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)Pivotal-lookingRecruiting
Laboratoires TheaIndustry
NCT06891443 · 32 participants (planned) · Start Jun 4, 2025 · Primary completion Nov 2027
Drug: sepofarsen · For: Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis and 7 more
Sites: San Francisco, California; Miami, Florida; Iowa City, Iowa · 18 sites in all
- An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.Pivotal-lookingStatus unknown
ProQR TherapeuticsIndustry
NCT04855045 · 15 participants (planned) · Start Mar 23, 2021 · Primary completion Dec 2023
Drug: sepofarsen · For: Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis and 8 more
Sites: Ghent, Belgium; Belo Horizonte, Brazil; São Paulo, Brazil · 9 sites in all
Laboratoires TheaIndustry
NCT03140969 · 11 participants · Start Oct 16, 2017 · Primary completion Oct 2, 2019
Drug: QR-110 · For: Leber's Congenital Amaurosis
Sites: Iowa City, Iowa; Philadelphia, Pennsylvania; Ghent, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy, Safety, and Durability of Gene Therapy for Inherited Retinal Diseases in the Pediatric Population: A Scoping Review.
Amato A, Iarossi G, Stephenson KA · Am J Ophthalmol 2026
- Ora visual navigation courseࡊ mobility test results in two individuals with CEP290 LCA after intravitreal injection of antisense oligonucleotide.
Marques C, Rodrigues GD, da Silva Martins EA, et al. · Ophthalmic Genet 2026
- Clinical Research for Inherited Retinal Disease Related Pediatric Blindness: A Preliminary Descriptive Analysis Based on ClinicalTrials.gov.
Ashour AM, Harbi MH, Alshehri FS, et al. · J Multidiscip Healthc 2025
- Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyes.
Cideciyan AV, Jacobson SG, Ho AC, et al. · Am J Ophthalmol Case Rep 2023
- RNA-based therapies in inherited retinal diseases.
Girach A, Audo I, Birch DG, et al. · Ther Adv Ophthalmol 2022
- Restoration of Cone Sensitivity to Individuals with Congenital Photoreceptor Blindness within the Phase 1/2 Sepofarsen Trial.
Cideciyan AV, Jacobson SG, Ho AC, et al. · Ophthalmol Sci 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.